For The Atlantic, Visiting Senior Fellow at American Economic Liberties Project Leo Wise wrote How Corruption Got This Bad. Wise reports that he ended his career in the specialized DOJ unit that prosecuted public corruption around the USA until it was effectively shut down by the Trump administration in 2025.
Wise explained his concern:
As a former federal prosecutor, the question I get asked most is “Isn’t that illegal?” Too often the answer is no. Over the past 40 years, the Supreme Court has narrowed our anti-corruption laws, case by case, until a lot of conduct that any juror would call corruption is now legal. I saw it from the inside. In 20 years at DOJ, I had to turn away cases I knew I could never make stick because of these rulings. In a new piece for The Atlantic, I walk through how we got here, from McNally to McDonnell to Snyder to the Trump immunity decision, and what Congress can do about it. Most of the damage came from the Court reading statutes narrowly, which means Congress can fix most of it by passing new laws. The next Congress should make that a priority.
Wise describes how Donald Trump, his family, and other American politicians have received enormously valuable benefits from people seeking and receiving government favours. In the cases he described, public power serves private enrichment, without meaningful accountability.
Supreme Court decisions have steadily weakened that accountability. In its 1999 Sun-Diamond decision, the Court ruled that giving lavish gifts to public officials and receiving benefits in return was insufficient to establish an offence. Going even further for Trump in 2024, the Court granted presidents criminal immunity for all official actions and even those in their private affairs.
As Wise puts it, “This isn’t partisan politics; it’s political elites protecting political elites.”
Canada has its own problem with the relationship between political power and corporate wealth. Too often, our old-line parties appear more responsive to large corporations than to small businesses and individuals. Politicians need not accept envelopes of cash to serve corporate interests. Shared assumptions, privileged access, and careers moving between government and business can produce policies that favour the already powerful.
Conduct can be lawful and still undermine the public interest.
Challenging that concentration of power is the purpose of the American Economic Liberties Project. Funded by foundations and individuals, it advocates for vigorous investigations, strong antitrust enforcement, anti-corruption measures, corporate accountability, and public agencies equipped to enforce the rules. Its goal is to challenge monopolistic corporate’ dominance over markets and society.
Canada needs the same determination to confront concentrated corporate power. The Canadian Anti-Monopoly Project provides a voice for that effort, combining research, public advocacy, and proposals to strengthen competition and curb monopoly power.
“Competition problems do not stop at national borders, especially in markets shaped by large multinational companies,” said Keldon Bester, Executive Director of the Canadian Anti-Monopoly Project.
Categories: Accountability, Economics, USA


A surprise from India?
Indian court orders Big Pharma to cut drug costs?
https://www.theguardian.com/global-development/2026/oct/23/india-cuts-cost-cancer-drugs
India slashes cost of cancer drugs after court rules mark-ups are ‘extortion’
Case filed in 2022 by patient unable to afford medicine leads to cap on drug prices for millions who face ruin if diagnosed
The Indian government has moved to reduce the price of cancer drugs after a retired bank clerk took her case to the supreme court.
From next month, 137 cancer drugs in India will be cheaper as the government tries to tackle the tragedy of poorer patients either forgoing treatment, selling land or falling into debt to meet the high cost of some medicines, which are making large profits for hospitals and pharmacists.
Sarojam Radhakrishnan, a former bank employee in Kerala, was diagnosed with breast cancer in 2021. Doctors prescribed life-saving targeted treatments but the monthly cost, of more than 63,000 rupees (£500), was far beyond her family’s means.
Realising that thousands of families were being ruined by the cost of such drugs, Radhakrishnan filed a petition to the Kerala high court in 2022 demanding government intervention to lower the costs.
When the case reached the supreme court, the judges looked at hospitals’ and retailers’ mark-ups on cancer drugs and called the situation “carnage” and “extortion”.
During a hearing on 29 September, justices Vikram Nath and Sandeep Mehta noted how a life-saving cancer drug supplied to hospitals at 2,700 rupees carried a vastly marked-up price of 27,000 rupees.
The judges found that hospitals, distributors and chemists enjoyed large margins on medicines. Analysis by the National Pharmaceutical Pricing Authority revealed a trade mark-up on some cancer drugs averaging 170%, with some extreme examples stretching to more than 700%.
A 30% trade margin cap on the price of 42 drugs has been in place for some years but many others remained off this list. Now, prodded by the supreme court’s findings, the government has imposed the cap on 137 other drugs.
“The measure is expected to reduce medicine prices by up to 70% and help cancer patients save 2,500 crore rupees [£199m] annually, significantly reducing the amount they pay from their own pockets,” a statement from the Department of Pharmaceuticals said.
LikeLike